Kazia Therapeutics Limited(KZIA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KZIA Kazia Therapeutics Limited

盘前交易 10-01 05:18:17 EDT

9.60

-0.15

-1.59%

最高9.90	最低9.46	成交量18.81万
今开9.90	昨收9.75	日振幅4.51%
总市值1.34亿	流通市值1.12亿	总股本1,401万
成交额181.07万	换手率1.61%	流通股本1,166万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KZIA","market":"US","secType":"STK","nameCN":"Kazia Therapeutics Limited","latestPrice":9.595,"timestamp":1790798400000,"preClose":9.75,"halted":0,"volume":188121,"delay":0,"changeRate":-0.015897435897435832,"floatShares":11656199,"shares":14006900,"eps":-6.819035,"marketStatus":"盘前交易","change":-0.155,"latestTime":"10-01 05:18:17 EDT","open":9.9,"high":9.9,"low":9.46,"amount":1810668.575541,"amplitude":0.045128,"askPrice":13.02,"askSize":100,"bidPrice":9.35,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-6.819035,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"adrRate":500,"exchange":"NASDAQ","adjPreClose":9.595,"postHourTrading":{"tag":"盘后","latestPrice":9.595,"preClose":9.595,"latestTime":"19:30 EDT","volume":10,"amount":95.95,"timestamp":1790811002675,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5230468008127486,"impliedVol":1.218,"impliedVolPercentile":0.0765},"requestUrl":"/m/hq/s/KZIA","defaultTab":"news","newsList":[{"id":"1148263570","title":"Kazia Therapeutics宣布：Sovargen联合公司已在帕昔利布治疗罕见癫痫疾病的1B/2a期试验中完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1148263570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148263570?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:31","pubTimestamp":1790076675,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics今日发布重大公告，宣布其合作伙伴Sovargen Co.已在帕昔利布针对罕见癫痫疾病的1B/2a期临床试验中，完成首例患者给药。帕昔利布作为一种创新性治疗候选药物，此次临床试验的启动无疑为饱受罕见癫痫困扰的患者群体带来了新的希望。Kazia Therapeutics方面表示，Sovargen Co.作为该试验的协作方，已顺利推进至患者入组阶段。市场分析师指出，Kazia Therapeutics此番消息的发布，不仅彰显了其在神经系统疾病治疗领域的战略布局，更凸显了与Sovargen Co.之间合作关系的实质性推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121080743","title":"Kazia Therapeutics宣布PNOC035临床研究首位患者完成给药，评估Paxalisib治疗复发性儿童AT/RT脑癌疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1121080743","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121080743?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:32","pubTimestamp":1788953561,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics Limited今日宣布，其评估Paxalisib用于复发性儿童非典型畸胎样/横纹肌样瘤的PNOC035临床研究，已完成首位患者给药。PNOC035研究由太平洋儿童神经肿瘤学联盟牵头开展，旨在深入评估Paxalisib在复发或难治性儿童脑癌患者中的安全性、耐受性及初步抗肿瘤活性。Kazia Therapeutics首席执行官John Friend博士表示，首位患者给药是这项研究的重要一步，期待Paxalisib能够为这一亟需新疗法的患者群体带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145784120","title":"Kazia Therapeutics公布临床前数据：Paxalisib可重编程免疫治疗耐药的MSS/pMMR结直肠癌并增强免疫治疗应答","url":"https://stock-news.laohu8.com/highlight/detail?id=1145784120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145784120?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262289,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics于今日披露了关键的临床前研究结果。数据显示，其在研药物Paxalisib能够对免疫治疗耐药的微卫星稳定型/错配修复功能完整型结直肠癌进行重编程，从而显著提升免疫治疗的疗效。众所周知，MSS/pMMR类型的结直肠癌对现有免疫疗法反应欠佳，一直是肿瘤治疗领域的难点。Kazia Therapeutics强调，这些数据为后续临床开发奠定了坚实基础。公司正积极评估Paxalisib在结直肠癌及其他实体瘤中的应用潜力，以期解决这一高度未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138979725","title":"Kazia Therapeutics二期试验预计2027年第一季度启动入组，年底前完成全部招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1138979725","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138979725?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262288,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics（KZIA）宣布，其二期试验的患者入组工作预计将于2027年第一季度正式启动，并计划在2027年底前实现全部入组目标。这一时间表标志着该临床项目进入关键推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181542089","title":"Kazia Therapeutics计划开展Paxalisib单药及联合帕博利珠单抗的五臂II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1181542089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181542089?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262282,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics Limited宣布，其正筹划一项涵盖五个治疗组的II期临床试验，旨在评估Paxalisib作为单药疗法以及与帕博利珠单抗联合使用的疗效。该试验设计体现了公司对多维度探索治疗潜力的战略布局。值得注意的是，五臂设计不仅囊括了单药治疗组，还设置了多种联合给药方案，以全面比较不同治疗策略下的临床获益。这一举措或将为相关适应症的治疗格局带来新的启示，也标志着Kazia在肿瘤精准医疗领域的又一关键推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165043700","title":"Kazia Therapeutics：Paxalisib单药治疗减轻肿瘤负担，联合Pembrolizumab进一步增效","url":"https://stock-news.laohu8.com/highlight/detail?id=1165043700","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165043700?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262277,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics公布最新研究进展——Paxalisib作为单药疗法，成功降低了肿瘤负担。更令人瞩目的是，当加入Pembrolizumab后，疗效得到进一步显著提升，肿瘤负担呈现更大幅度的缩减。这一发现为联合治疗策略提供了有力证据，或有望为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190879896","title":"Kazia Therapeutics扩展Paxalisib临床试验至HR+/HER2-乳腺癌，临床前数据显示其在HR+乳腺癌中具有强效活性与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1190879896","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190879896?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics宣布，将Paxalisib的临床试验范围扩展至HR+/HER2-乳腺癌领域。这一决策背后，有坚实的临床前数据作为支撑——这些数据清晰地展示了Paxalisib在HR+乳腺癌中的显著临床活性与良好的安全特性。Paxalisib作为一种在研药物，其潜力正在被逐步挖掘。Kazia Therapeutics此次行动，标志着其在肿瘤治疗领域的又一重要布局。整体来看，这一战略举措反映了Kazia Therapeutics致力于推进创新疗法的决心。随着试验的深入，Paxalisib的临床应用前景或将更加明朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118847604","title":"Kazia Therapeutics提交招股文件：拟发行95,110股美国存托股份，对应47,555,000股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118847604","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118847604?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:34","pubTimestamp":1788176049,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，Kazia Therapeutics Limited（KZIA）已正式提交一份招股说明书，计划发行95,110股美国存托股份（ADS）。据了解，这批ADS所代表的标的证券数量颇为可观——换算下来，其背后对应的普通股总数高达47,555,000股。这一发行安排，不仅牵动着现有股东的神经，也预示着公司未来资本运作的路径或将迎来新的变数。此次发行文件一经提交，便迅速引发了市场对于该公司融资意图及后续资金用途的广泛猜测与讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117421882","title":"Kazia Therapeutics提交文件：拟发行高达8000万美元的美国存托股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1117421882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117421882?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:13","pubTimestamp":1787911989,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics Limited已正式提交相关文件，计划发行总额高达8000万美元的美国存托股份，这些股份代表其普通股。这一消息源自该公司向美国证券交易委员会递交的备案文件。据悉，此次发行旨在为公司的未来发展筹集资金，具体规模与时间安排尚未完全敲定。投资者对此消息反应不一，部分人看好公司未来的成长潜力，而另一些人则对股权稀释的可能性持谨慎态度。后续进展，有待公司进一步披露详细计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118999557","title":"Kazia Therapeutics：所有患者循环肿瘤细胞簇中位降幅达83%，衰竭T细胞减少51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118999557","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118999557?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:02","pubTimestamp":1787860931,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics公布了一项最新临床数据，揭示了其治疗方案带来的显著免疫学改变。数据显示，所有受试患者的循环肿瘤细胞簇出现了令人瞩目的中位降幅——高达83%。与此同时，衰竭T细胞的数量也呈现出51%的中位减少。从更深层次看，CTC簇的显著下降可能意味着肿瘤转移风险的降低，而衰竭T细胞的减少则暗示着机体抗肿瘤免疫应答的潜在复苏。Kazia Therapeutics的这项发现，为其候选药物增添了颇具说服力的临床佐证，也引发了业界对其后续研究进展的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127970341","title":"Kazia Therapeutics：1B期研究预计2027年7月完成入组，2026至2027年间将陆续发布中期临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1127970341","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127970341?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:02","pubTimestamp":1787860929,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics宣布，其1B期研究的患者入组工作预计将于2027年7月收官。与此同时，公司计划在2026年和2027年期间，分阶段对外披露中期临床数据更新，为市场持续注入新的观察视角与判断依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173848470","title":"Kazia Therapeutics 提交新策略临时专利申请，临床前数据支持预防三阴性乳腺癌转移复发","url":"https://stock-news.laohu8.com/highlight/detail?id=1173848470","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173848470?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:31","pubTimestamp":1785238278,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics 正式宣布，已提交一项临时专利申请，旨在预防三阴性乳腺癌的转移性复发。这一创新策略的诞生，建立在前期临床前数据的强力支撑之上。值得注意的是，该疗法直指这类侵袭性乳腺癌复发时的棘手问题——远处转移。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159941648","title":"Kazia Therapeutics Limited董事会主席Bryce Carmine宣布将于2026年3月26日退休","url":"https://stock-news.laohu8.com/highlight/detail?id=1159941648","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159941648?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:08","pubTimestamp":1775038094,"startTime":"0","endTime":"0","summary":"2026年3月26日，Kazia Therapeutics Limited现任董事会主席Bryce Carmine正式向董事会通报其退休意向。这一重大人事变动标志着公司治理层即将迎来新的篇章。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518222567","title":"Kazia Therapeutics Limited盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518222567?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:36","pubTimestamp":1741613793,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时36分，Kazia Therapeutics Limited股票出现波动，股价大幅下挫5.08%。截至发稿，该股报1.12美元/股，成交量19.3999万股，换手率3.47%，振幅5.08%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体涨幅为0.42%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213633abf2fe3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213633abf2fe3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZIA","LENZ","BK4139","NVGNF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517161311","title":"Kazia Therapeutics Limited盘中异动 大幅拉升7.33%报0.848美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517161311?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:59","pubTimestamp":1741273143,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时59分，Kazia Therapeutics Limited股票出现波动，股价急速拉升7.33%。截至发稿，该股报0.848美元/股，成交量1165股，换手率0.02%，振幅7.33%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体跌幅为0.63%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306225903abeb7e9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306225903abeb7e9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZIA","LENZ","NVGNF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948806","title":"Kazia Therapeutics Limited盘中异动 股价大涨6.06%报0.810美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948806","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948806?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185143,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Kazia Therapeutics Limited股票出现异动，股价大幅拉升6.06%。截至发稿，该股报0.810美元/股，成交量4.5971万股，换手率0.82%，振幅0.00%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体涨幅为0.20%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223223abe9b0fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223223abe9b0fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KZIA","BK4139","NVGNF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517833819","title":"Kazia Therapeutics Limited盘中异动 急速下跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517833819","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517833819?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:33","pubTimestamp":1741116814,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时33分，Kazia Therapeutics Limited股票出现波动，股价大幅跳水5.16%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1311.19%、1224.04%、1209.16%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033334a25f57f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033334a25f57f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NVGNF","LENZ","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514861729","title":"Kazia Therapeutics Limited盘中异动 急速上涨5.62%报0.864美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514861729?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:38","pubTimestamp":1740598693,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时38分，Kazia Therapeutics Limited股票出现异动，股价急速上涨5.62%。截至发稿，该股报0.864美元/股，成交量3.8845万股，换手率0.69%，振幅5.28%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体跌幅为0.47%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270338139631862c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270338139631862c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVGNF","BK4139","LENZ","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514016510","title":"Kazia Therapeutics Limited盘中异动 早盘股价大跌8.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514016510?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:30","pubTimestamp":1740497415,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时30分，Kazia Therapeutics Limited股票出现异动，股价大幅下跌8.34%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体涨幅为0.78%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1070.68%、947.53%、593.23%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、64.05%、61.16%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225233015a253950e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225233015a253950e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KZIA","NVGNF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512348187","title":"Kazia Therapeutics Limited盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512348187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512348187?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:02","pubTimestamp":1739980942,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时02分，Kazia Therapeutics Limited股票出现异动，股价急速下挫5.00%。Kazia Therapeutics Limited股票所在的生物技术行业中，整体涨幅为0.46%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为561.88%、242.60%、178.48%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Aditxt, Inc.，振幅分别为207.68%、159.49%、48.18%。Kazia Therapeutics Limited公司简介：Kazia Therapeutics Ltd是一家专注于肿瘤的生物技术公司，开发抗癌药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000223a24c0cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000223a24c0cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NVGNF","LENZ","KZIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kaziatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.3032},{"period":"3month","weight":-0.2758},{"period":"6month","weight":0.3072},{"period":"1year","weight":0.3308},{"period":"ytd","weight":0.3926}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kazia Therapeutics Limited成立于1994年3月，注册地为澳大利亚新南威尔士州。该公司从事药物开发，主要专注于肿瘤学。Kazia是一家新兴的生物技术企业，拥有涵盖多种技术的开发候选产品组合，旨在推进针对各种癌症适应症的创新疗法，并提供解决未满足的医疗需求的新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.481481,"avgChangeRate":0.051769},{"month":2,"riseRate":0.285714,"avgChangeRate":0.031553},{"month":3,"riseRate":0.5,"avgChangeRate":0.046817},{"month":4,"riseRate":0.428571,"avgChangeRate":0.032014},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.030245},{"month":6,"riseRate":0.357143,"avgChangeRate":-0.051178},{"month":7,"riseRate":0.357143,"avgChangeRate":0.006275},{"month":8,"riseRate":0.428571,"avgChangeRate":0.006107},{"month":9,"riseRate":0.464286,"avgChangeRate":-0.014247},{"month":10,"riseRate":0.37037,"avgChangeRate":-0.038599},{"month":11,"riseRate":0.481481,"avgChangeRate":0.165037},{"month":12,"riseRate":0.407407,"avgChangeRate":-0.048165}],"exchange":"NASDAQ","name":"Kazia Therapeutics Limited","nameEN":"Kazia Therapeutics Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kazia Therapeutics Limited(KZIA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kazia Therapeutics Limited(KZIA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kazia Therapeutics Limited,KZIA,Kazia Therapeutics Limited股票,Kazia Therapeutics Limited股票老虎,Kazia Therapeutics Limited股票老虎国际,Kazia Therapeutics Limited行情,Kazia Therapeutics Limited股票行情,Kazia Therapeutics Limited股价,Kazia Therapeutics Limited股市,Kazia Therapeutics Limited股票价格,Kazia Therapeutics Limited股票交易,Kazia Therapeutics Limited股票购买,Kazia Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kazia Therapeutics Limited(KZIA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kazia Therapeutics Limited(KZIA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}